Table 1.

Baseline patient demographic and disease characteristics

Characteristic	Patients (n = 40)
Age, median (range), y	65 (39-79)
18–65 y, n (%)	21 (52.5)
>65 y, n (%)	19 (47.5)
Male, n (%)	22 (55.0)
ECOG PS, n (%)
0	16 (40.0)
1	22 (55.0)
2	2 (5.0)
Ann Arbor stage at study entry, n (%)
I to II	6 (15.0)
III to IV	34 (85.0)
IPI score at study entry, n (%)
2	19 (47.5)
3	15 (37.5)
4	6 (15.0)
Cell of origin by local laboratory, n (%)
Germinal center B cell	17 (42.5)∗
Nongerminal center B cell	21 (52.5)†
Unknown	2 (5.0)
Additional characterization by local laboratory, n (%)
Rearrangements of MYC, BCL2, and/or BCL6	3 (7.5)
Double expressor (MYC and BCL2 overexpression without translocation)	6 (15.0)‡
None of the above	28 (70.0)
Not determined/available	3 (7.5)

ECOG PS, Eastern Cooperative Oncology Group performance status; GEP, gene expression profiling; IHC, immunohistochemistry.

^∗Thirteen patients assigned based on IHC and 4 assigned based on GEP.

^†Seventeen patients assigned based on IHC and 4 patients based on GEP (3 had activated B cell, and 1 was unclassified).

^‡Includes 1 patient whose double expressor status was not confirmed until after the clinical cutoff date.